Join us on Thursday, February, February 4^th for this CME-accredited webinar
5:00 PM – 6:30 PM ET

This activity is supported by educational grants from Astellas, AstraZeneca Pharmaceuticals LP, Daiichi Sankyo Inc, Five Prime Therapeutics Inc, Lilly and Taiho Oncology Inc.

Not an official event of the 2021 Gastrointestinal Cancers Symposium. Not sponsored, endorsed, or accredited by any of the cosponsoring organizations of the 2021 Gastrointestinal Cancers Symposium.

Thursday, February 4, 2021
5:00 PM – 6:30 PM Eastern Time
Live CME-accredited webinar

Topics to Be Discussed

• Evolving Front-Line Management of Advanced Gastric and Gastroesophageal Junction (GEJ) Cancer
• Selection and Sequencing of Therapies for Relapsed Gastric or GEJ Cancer; Novel Investigational Approaches
• Current and Future Management of HER2-Positive Advanced Gastric/GEJ Cancer
• Key Research Informing the Treatment of Localized and Advanced Esophageal Cancer

A detailed agenda will be provided in the coming weeks.

Target Audience
This activity is intended for medical oncologists, hematology-oncology fellows, surgeons and other healthcare professionals involved in the treatment of gastrointestinal cancer.

Learning Objectives
Upon completion of this activity, participants should be able to

• Use HER2 status, PD-L1 combined positive score, clinical factors and patient preferences to personalize the selection and sequence of systemic therapy for locally advanced or metastatic gastric or gastroesophageal junction (GEJ) cancer.
• Describe the published research data with the use of immune checkpoint inhibitors alone or in combination with chemotherapy in the management of gastric/GEJ cancer, and optimally integrate these strategies into nonresearch treatment algorithms.
• Recall the biologic rationale for and available data with the use of trastuzumab deruxtecan for previously treated HER2-overexpressing gastric/GEJ cancer, and discern the current and potential applicability of this treatment strategy.
• Devise a rational approach to the incorporation of TAS-102 into the treatment algorithm for previously treated locally advanced or metastatic gastric/GEJ cancer.
• Appreciate the recent FDA approvals of pembrolizumab and nivolumab for previously treated squamous cell carcinoma of the esophagus, and identify patients appropriate for treatment with either of these novel agents.
• Appraise recently presented clinical trial findings with and potential roles for anti-PD-1 antibodies as adjuvant therapy or as a component of first-line treatment for patients with esophageal cancer.
• Review the rationale for, available data with and ongoing research evaluating novel agents and strategies for gastroesophageal cancers, and effectively prioritize clinical trial opportunities for eligible patients.

CME Credit Form
A CME credit form will be emailed to participants within 3 business days of the activity.

Accreditation Statement
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation Statement
Research To Practice designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Content Validation and Disclosures
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CME activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTY — The following faculty (and their spouses/partners) reported relevant conflicts of interest, which have been resolved through a conflict of interest resolution process:

Dr Catenacci — Advisory Committee: Astellas, Merck, Seagen Inc, Tempus; Consulting Agreements: Amgen Inc, Archer Pharmaceuticals, Astellas, Bristol-Myers Squibb Company, Daiichi Sankyo Inc, Five Prime Therapeutics Inc, Foundation Medicine, Genentech, a member of the Roche Group, Gritstone Oncology, Guardant Health, Lilly, Merck, Natera Inc, Pieris Pharmaceuticals Inc, QED Therapeutics, Seagen Inc, Taiho Oncology Inc, Tempus, Zymeworks; Contracted Research: Amgen Inc, Genentech, a member of the Roche Group; Data and Safety Board: Genentech, a member of the Roche Group, Merck Serono; Speakers Bureau: Genentech, a member of the Roche Group, Guardant Health, Lilly, Merck, Tempus. Dr Janjigian — Consulting Agreements: AstraZeneca Pharmaceuticals LP, Basilea Pharmaceutica Ltd, Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb Company, Daiichi Sankyo Inc, Imugene, Lilly, Merck, Merck Serono, Pfizer Inc, Rgenix, Zymeworks; Contracted Research: Bayer HealthCare Pharmaceuticals, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Genentech, a member of the Roche Group, Lilly, Merck, Rgenix; Ownership Interest (Stock Options): Rgenix. Dr Mehta — Advisory Committee: Bristol-Myers Squibb Company, Taiho Oncology Inc; Consulting Agreement: Lilly; Science Review Committee: NCCN. Dr Wainberg — Consulting Agreements: Amgen Inc, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb Company, Daiichi Sankyo Inc, Five Prime Therapeutics Inc, Gilead Sciences Inc, Ipsen Biopharmaceuticals Inc, Lilly, Merck, Molecular Templates; Contracted Research: Arcus Biosciences, Five Prime Therapeutics Inc, Novartis, Plexxikon Inc; Data and Safety Monitoring Board/Committee: Array BioPharma Inc, a subsidiary of Pfizer Inc, Pfizer Inc.

MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Acerta Pharma — A member of the AstraZeneca Group, Adaptive Biotechnologies Corporation, Agendia Inc, Agios Pharmaceuticals Inc, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Biodesix Inc, bioTheranostics Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Daiichi Sankyo Inc, Dendreon Pharmaceuticals Inc, Eisai Inc, EMD Serono Inc, Epizyme Inc, Exact Sciences Inc, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, Genentech, a member of the Roche Group, Genmab, Gilead Sciences Inc, GlaxoSmithKline, Grail Inc, Guardant Health, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Infinity Pharmaceuticals Inc, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Lexicon Pharmaceuticals Inc, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Merrimack Pharmaceuticals Inc, Myriad Genetic Laboratories Inc, Natera Inc, Novartis, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Prometheus Laboratories Inc, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sandoz Inc, a Novartis Division, Sanofi Genzyme, Seagen Inc, Sirtex Medical Ltd, Spectrum Pharmaceuticals Inc, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Oncology, Tesaro, A GSK Company, Teva Oncology, Tokai Pharmaceuticals Inc and Verastem Inc.

Research To Practice CME Planning Committee Members, Staff and Reviewers — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

Supporters
This activity is supported by educational grants from Astellas, AstraZeneca Pharmaceuticals LP, Daiichi Sankyo Inc, Five Prime Therapeutics Inc, Lilly and Taiho Oncology Inc.